Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Mar;31(3):440-441.
doi: 10.1016/j.annonc.2019.11.016. Epub 2019 Dec 9.

Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification

M Mazzotta  1 , M Filetti  1 , A Rossi  1 , M Roberto  1 , M Occhipinti  2 , A Pernazza  3 , A Di Napoli  4 , S Scarpino  4 , A Vecchione  4 , R Giusti  5 , P Marchetti  6
Affiliations
Free article
Comment

Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification

M Mazzotta et al. Ann Oncol. 2020 Mar.
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest.

Comment on

  • Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
    Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G. Moro-Sibilot D, et al. Ann Oncol. 2019 Dec 1;30(12):1985-1991. doi: 10.1093/annonc/mdz407. Ann Oncol. 2019. PMID: 31584608 Clinical Trial.